BC Partners Ltd, Onex Corp and American Securities LLC are competing for Ikaria Inc, a private equity and venture capital-backed specialty drug company that may fetch up to $2 billion, according to people familiar with the matter. The three private equity firms are among those through to the second round of bidding for Ikaria, with final offers currently due by early December, the people said this week on condition of anonymity because the process is confidential.Ikaria, BC Partners and American Securities failed to comment while an Onex spokeswoman did not respond to a request for comment.Hampton, New Jersey-based Ikaria's main drug INOMAX delivers nitric oxide gas to treat newborns with serious trouble breathing, allowing for more oxygenated blood to circulate in their bodies. It also has a pipeline of what it calls "critical care" products for patients with life-threatening injuries or disease.Ikaria, whose owners include New Mountain Capital LLC, ARCH Venture Partners LP and Venrock Associates LP, is working with Morgan Stanley and Credit Suisse Group AG on the possible sale, people familiar with the matter told Reuters last month.
Credit Suisse Group AG (Credit Suisse) is a global financial services company. Shares of CS remained unchanged at $28.56. In the past year, the shares have traded as low as $22.10 and as high as $33.98. On average, 1080170 shares of CS exchange hands on a given day and today's volume is recorded at 2500.
Morgan Stanley is a global financial services company that, through its subsidiaries and affiliates, provides its products and services to a range of clients and customers, including corporations, governments, financial institutions and individuals. Shares of MS remained unchanged at $30.89. In the past year, the shares have traded as low as $16.23 and as high as $30.78. On average, 13173400 shares of MS exchange hands on a given day and today's volume is recorded at 0.
Source
